UMIN-CTR History

Name:  UMIN ID:


Unique ID issued by UMIN UMIN000018722
Receipt number R000021098
Scientific Title Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with tri-weekly docetaxel (D) followed by doxorubicin, 5-fluorouracil, and cyclophosphamide (FEC) or docetaxel with concurrent use of capecitabine (TX) followed by doxorubicin, cyclophosphamide, and capecitabine (CEX) in women with locally advanced triple-negative breast cancer
Date of disclosure of the study information 2015/10/01
Last modified on 2017/08/29 11:41:49

No. Disposal Last modified on Item of update
1 Insert 2015/08/19 12:56:38
2 Update 2015/08/20 10:44:25 Target sample size
3 Update 2017/08/29 11:41:49 Name of primary person or sponsor
Organization